Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06110195 · ClinicalTrials.gov registry record · Phase 1

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

A Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by University of Chicago.

Active
Registry status
Phase 1
Development phase
42
Enrollment target
1
Study location

NCT06110195 is a Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 42 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06110195, a Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by University of Chicago.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to determine the best safe dose of xevinapant that can be given in combination with chemotherapy and radiation in patients with head and neck cancer. Up to 4 doses of xevinapant will be tested in the dose escalation portion of the study. After the best safe dose is found during escalation, an additional group of participants will be enrolled at that dose to learn more about the treatment combination (dose expansion). The main question\[s\] it aims to answer are: * what is the maximum safe dose that can be given * what dose should be used in subsequent (phase 2) trials Participants will receive xevinapant in combination with paclitaxel and carboplatin chemotherapy and radiation. Treatment will be given in 3-week cycles for 3 cycles.

Conditions Studied

Head and Neck Cancer Squamous Cell Carcinoma of Head and Neck Head and Neck Neoplasms

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • RADIATION Radiation Therapy
  • DRUG Xevinapant

Study Locations (1)

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2024-01-24
Est. Completion 2027-10
Phase Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06110195

The ClinicalTrials.gov registry entry for NCT06110195 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (84% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT06110195 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06110195 about?

NCT06110195 is a clinical study titled "Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer". The goal of this clinical trial is to determine the best safe dose of xevinapant that can be given in combination with chemotherapy and radiation in patients with head and neck cancer. Up to 4 doses of xevinapant will be tested in the dose escalation portion of the study. After the best safe dose is...

What is the current status of trial NCT06110195?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2024-01-24. Estimated completion is 2027-10.

What conditions does trial NCT06110195 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms.

What interventions are being tested in trial NCT06110195?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiation Therapy (RADIATION), Xevinapant (DRUG).

Who is sponsoring clinical trial NCT06110195?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06110195 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.